Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03812510 · ClinicalTrials.gov registry record · Phase 3
Safety Study of A-101 Topical Solution for the Treatment of Common Warts
A Phase 3 study of Common Wart, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 426
- Enrollment target
- 20
- Study locations
NCT03812510: Completed Phase 3 study of Common Wart, sponsored by Aclaris Therapeutics.
NCT03812510 is a Phase 3 study of Common Wart that has completed, run by Aclaris Therapeutics. The registered enrollment target is 426 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03812510, a Phase 3 study of Common Wart, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 426 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts
Primary Outcome
Safety exposure will be measured by the proportion of subjects exposed to A-101 45% who have emergent adverse events. In order to be eligible for A-101-WART-303, subjects must have completed protocol treatment on either the A-101-WART-301 or A-101-WART-302 study. The A-101-WART-303 study was an open-label with a single arm where all subjects received A-101 Topical Solution 45% twice a week. Since A-101-WART-303 is an extension study, statistical analyses were performed by stratifying patients by
Conditions Studied
Interventions
- DRUG A-101
Study Locations (20)
Florida
- Aclaris Investigational Site - Aventura
- Aclaris Investigational Site - Jacksonville
- Aclaris Investigational Site - Miami
- Aclaris Investigational Site - Miami
- Aclaris Investigational Site - Ocala
California
- Aclaris Investigational Site - Encinitas
- Aclaris Investigational Site - Fountain Valley
- Aclaris Investigational Site - San Diego
- Aclaris Investigational Site - San Diego
Arkansas
- Aclaris Investigational Site - Fort Smith
- Aclaris Investigational Site - Hot Springs
Indiana
- Aclaris Investigational Site - Indianapolis
- Aclaris Investigational Site - New Albany
Alabama
- Aclaris Investigational Site - Mobile
Arizona
- Aclaris Investigational Site - Glendale
Colorado
- Aclaris Investigational Site - Denver
Georgia
- Aclaris Investigational Site - Newnan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2019-12-20 |
| Phase | Phase 3 |
What the finished NCT03812510 record still lists
NCT03812510 is an interventional study that assigns participants to a tested intervention. The registered 426 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Common Wart appearing as the primary indexed condition, and to 1 intervention - of which A-101 is the first listed.
NCT03812510 names 20 study sites across 11 states, led by Florida, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03812510 about?
NCT03812510 is a clinical study titled "Safety Study of A-101 Topical Solution for the Treatment of Common Warts". A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts
What is the current status of trial NCT03812510?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 426 participants. The study started on 2019-02-07. Estimated completion is 2019-12-20.
What conditions does trial NCT03812510 study?
This clinical trial studies the following conditions: Common Wart.
What interventions are being tested in trial NCT03812510?
The interventions under investigation include: A-101 (DRUG).
Who is sponsoring clinical trial NCT03812510?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03812510 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Common Wart
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03812510's enrollment target sits among peer trials
426 882nd of 2000 higher than 1,118 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06790784 · 426 participants · Phase 3
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
- NCT04265430 · 425 participants · Phase 4
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors
- NCT04278690 · 425 participants · NA
Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit
- NCT05321368 · 425 participants · NA
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI